Cargando…
No benefit of HIF prolyl hydroxylase inhibition for hypertensive renal damage in renovascular hypertensive rats
Introduction: We previously reported that malignant hypertension is associated with impaired capillary density of target organs. Here, we tested the hypothesis that stabilization of hypoxia-inducible factor (HIF) in a modified “preconditioning” approach prevents the development of malignant hyperten...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331609/ https://www.ncbi.nlm.nih.gov/pubmed/37435301 http://dx.doi.org/10.3389/fphys.2023.1208105 |
_version_ | 1785070291427262464 |
---|---|
author | Hartner, Andrea Dambietz, Thomas Cordasic, Nada Willam, Carsten Burzlaff, Nicolai Brötsch, Martin Daniel, Christoph Schiffer, Mario Amann, Kerstin Veelken, Roland Schley, Gunnar Hilgers, Karl F. |
author_facet | Hartner, Andrea Dambietz, Thomas Cordasic, Nada Willam, Carsten Burzlaff, Nicolai Brötsch, Martin Daniel, Christoph Schiffer, Mario Amann, Kerstin Veelken, Roland Schley, Gunnar Hilgers, Karl F. |
author_sort | Hartner, Andrea |
collection | PubMed |
description | Introduction: We previously reported that malignant hypertension is associated with impaired capillary density of target organs. Here, we tested the hypothesis that stabilization of hypoxia-inducible factor (HIF) in a modified “preconditioning” approach prevents the development of malignant hypertension. To stabilize HIF, we employed pharmacological inhibition of HIF prolyl hydroxylases (PHD), that profoundly affect HIF metabolism. Methods: Two-kidney, one-clip renovascular hypertension (2K1C) was induced in rats; controls were sham operated. 2K1C rats received either intermittent injections of the PHD inhibitor ICA (2-(1-chloro-4-hydroxyisoquinoline-3-carboxamido) acetate) or placebo. Thirty-five days after clipping, the frequency of malignant hypertension was assessed (based on weight loss and the occurrence of characteristic vascular lesions). In addition, kidney injury was compared between all ICA treated versus all placebo treated 2K1C, regardless of the occurrence of malignant hypertension. HIF stabilization was evaluated by immunohistochemistry, and HIF target gene expression by RT-PCR. Results: Blood pressure was elevated to the same degree in ICA- and placebo-treated 2K1C compared to control rats. ICA treatment did not affect the frequency of malignant hypertension or the extent of kidney tissue fibrosis, inflammation, or capillary density. There was a trend towards higher mortality and worse kidney function in ICA-treated 2K1C rats. ICA increased the number of HIF-1α-positive renal tubular cell nuclei and induced several HIF-1 target genes. In contrast, expression of HIF-2α protein as well as HIF-2 target genes were markedly enhanced by 2K1C hypertension, irrespective of ICA treatment. Discussion: We conclude that intermittent PHD inhibition did not ameliorate severe renovascular hypertension in rats. We speculate that the unexpected strong renal accumulation of HIF-2α in renovascular hypertension, which could not be further augmented by ICA, may contribute to the lack of a benefit from PHD inhibition. |
format | Online Article Text |
id | pubmed-10331609 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-103316092023-07-11 No benefit of HIF prolyl hydroxylase inhibition for hypertensive renal damage in renovascular hypertensive rats Hartner, Andrea Dambietz, Thomas Cordasic, Nada Willam, Carsten Burzlaff, Nicolai Brötsch, Martin Daniel, Christoph Schiffer, Mario Amann, Kerstin Veelken, Roland Schley, Gunnar Hilgers, Karl F. Front Physiol Physiology Introduction: We previously reported that malignant hypertension is associated with impaired capillary density of target organs. Here, we tested the hypothesis that stabilization of hypoxia-inducible factor (HIF) in a modified “preconditioning” approach prevents the development of malignant hypertension. To stabilize HIF, we employed pharmacological inhibition of HIF prolyl hydroxylases (PHD), that profoundly affect HIF metabolism. Methods: Two-kidney, one-clip renovascular hypertension (2K1C) was induced in rats; controls were sham operated. 2K1C rats received either intermittent injections of the PHD inhibitor ICA (2-(1-chloro-4-hydroxyisoquinoline-3-carboxamido) acetate) or placebo. Thirty-five days after clipping, the frequency of malignant hypertension was assessed (based on weight loss and the occurrence of characteristic vascular lesions). In addition, kidney injury was compared between all ICA treated versus all placebo treated 2K1C, regardless of the occurrence of malignant hypertension. HIF stabilization was evaluated by immunohistochemistry, and HIF target gene expression by RT-PCR. Results: Blood pressure was elevated to the same degree in ICA- and placebo-treated 2K1C compared to control rats. ICA treatment did not affect the frequency of malignant hypertension or the extent of kidney tissue fibrosis, inflammation, or capillary density. There was a trend towards higher mortality and worse kidney function in ICA-treated 2K1C rats. ICA increased the number of HIF-1α-positive renal tubular cell nuclei and induced several HIF-1 target genes. In contrast, expression of HIF-2α protein as well as HIF-2 target genes were markedly enhanced by 2K1C hypertension, irrespective of ICA treatment. Discussion: We conclude that intermittent PHD inhibition did not ameliorate severe renovascular hypertension in rats. We speculate that the unexpected strong renal accumulation of HIF-2α in renovascular hypertension, which could not be further augmented by ICA, may contribute to the lack of a benefit from PHD inhibition. Frontiers Media S.A. 2023-06-26 /pmc/articles/PMC10331609/ /pubmed/37435301 http://dx.doi.org/10.3389/fphys.2023.1208105 Text en Copyright © 2023 Hartner, Dambietz, Cordasic, Willam, Burzlaff, Brötsch, Daniel, Schiffer, Amann, Veelken, Schley and Hilgers. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Physiology Hartner, Andrea Dambietz, Thomas Cordasic, Nada Willam, Carsten Burzlaff, Nicolai Brötsch, Martin Daniel, Christoph Schiffer, Mario Amann, Kerstin Veelken, Roland Schley, Gunnar Hilgers, Karl F. No benefit of HIF prolyl hydroxylase inhibition for hypertensive renal damage in renovascular hypertensive rats |
title | No benefit of HIF prolyl hydroxylase inhibition for hypertensive renal damage in renovascular hypertensive rats |
title_full | No benefit of HIF prolyl hydroxylase inhibition for hypertensive renal damage in renovascular hypertensive rats |
title_fullStr | No benefit of HIF prolyl hydroxylase inhibition for hypertensive renal damage in renovascular hypertensive rats |
title_full_unstemmed | No benefit of HIF prolyl hydroxylase inhibition for hypertensive renal damage in renovascular hypertensive rats |
title_short | No benefit of HIF prolyl hydroxylase inhibition for hypertensive renal damage in renovascular hypertensive rats |
title_sort | no benefit of hif prolyl hydroxylase inhibition for hypertensive renal damage in renovascular hypertensive rats |
topic | Physiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331609/ https://www.ncbi.nlm.nih.gov/pubmed/37435301 http://dx.doi.org/10.3389/fphys.2023.1208105 |
work_keys_str_mv | AT hartnerandrea nobenefitofhifprolylhydroxylaseinhibitionforhypertensiverenaldamageinrenovascularhypertensiverats AT dambietzthomas nobenefitofhifprolylhydroxylaseinhibitionforhypertensiverenaldamageinrenovascularhypertensiverats AT cordasicnada nobenefitofhifprolylhydroxylaseinhibitionforhypertensiverenaldamageinrenovascularhypertensiverats AT willamcarsten nobenefitofhifprolylhydroxylaseinhibitionforhypertensiverenaldamageinrenovascularhypertensiverats AT burzlaffnicolai nobenefitofhifprolylhydroxylaseinhibitionforhypertensiverenaldamageinrenovascularhypertensiverats AT brotschmartin nobenefitofhifprolylhydroxylaseinhibitionforhypertensiverenaldamageinrenovascularhypertensiverats AT danielchristoph nobenefitofhifprolylhydroxylaseinhibitionforhypertensiverenaldamageinrenovascularhypertensiverats AT schiffermario nobenefitofhifprolylhydroxylaseinhibitionforhypertensiverenaldamageinrenovascularhypertensiverats AT amannkerstin nobenefitofhifprolylhydroxylaseinhibitionforhypertensiverenaldamageinrenovascularhypertensiverats AT veelkenroland nobenefitofhifprolylhydroxylaseinhibitionforhypertensiverenaldamageinrenovascularhypertensiverats AT schleygunnar nobenefitofhifprolylhydroxylaseinhibitionforhypertensiverenaldamageinrenovascularhypertensiverats AT hilgerskarlf nobenefitofhifprolylhydroxylaseinhibitionforhypertensiverenaldamageinrenovascularhypertensiverats |